These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 17040248)

  • 21. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KL-6: a serum marker for interstitial pneumonia.
    Kobayashi J; Kitamura S
    Chest; 1995 Aug; 108(2):311-5. PubMed ID: 7634858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.
    Ohnishi H; Yokoyama A; Kondo K; Hamada H; Abe M; Nishimura K; Hiwada K; Kohno N
    Am J Respir Crit Care Med; 2002 Feb; 165(3):378-81. PubMed ID: 11818324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies of serum markers in patients with interstitial pneumonia/pulmonary fibrosis complicated with collagen diseases: clinical evaluation of CYFRA21-1].
    Suzuki A; Masuda T; Koito N; Suzuki T; Mita S; Matsuoka Y; Irimajiri S
    Ryumachi; 1996 Dec; 36(6):837-43. PubMed ID: 9122823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia.
    Yokoyama A; Kohno N; Kondo K; Ueda S; Hirasawa Y; Watanabe K; Takada Y; Hiwada K
    Respirology; 1998 Sep; 3(3):199-202. PubMed ID: 9767620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Interstitial lung disease and lung cancer].
    Ishikawa N; Kohno N
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):6-9. PubMed ID: 20087026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum KL-6 as a marker for bronchiolitis obliterans syndrome after lung transplantation.
    Walter JN; Fan LL; Bag R; Zhang H; Doan M; Mallory GB; Elidemir O
    Transplantation; 2006 Sep; 82(5):709-11. PubMed ID: 16969297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral T-cell lymphoma with diffuse pulmonary infiltration and an increase in serum KL-6 level.
    Fujisawa T; Suda T; Matsuura S; Enomoto N; Takeshita K; Ohnishi K; Chida K
    Respirology; 2007 May; 12(3):452-4. PubMed ID: 17539855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi I; Ono S; Kawamura N; Okano M; Miyazawa K; Shibuya H; Kobayashi K
    J Pediatr; 2001 Feb; 138(2):274-6. PubMed ID: 11174630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome.
    Nakashima T; Yokoyama A; Ohnishi H; Hamada H; Ishikawa N; Haruta Y; Hattori N; Tanigawa K; Kohno N
    J Intern Med; 2008 Apr; 263(4):432-9. PubMed ID: 18298483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases.
    Kruit A; Gerritsen WB; Pot N; Grutters JC; van den Bosch JM; Ruven HJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2010 Jul; 27(2):138-46. PubMed ID: 21319596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts.
    Ohshimo S; Yokoyama A; Hattori N; Ishikawa N; Hirasawa Y; Kohno N
    Biochem Biophys Res Commun; 2005 Dec; 338(4):1845-52. PubMed ID: 16289035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis.
    Kumánovics G; Görbe E; Minier T; Simon D; Berki T; Czirják L
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-138-44. PubMed ID: 24773853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.
    Ohshimo S; Ishikawa N; Horimasu Y; Hattori N; Hirohashi N; Tanigawa K; Kohno N; Bonella F; Guzman J; Costabel U
    Respir Med; 2014 Jul; 108(7):1031-9. PubMed ID: 24835074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating levels of KL-6 in acute respiratory distress syndrome sepsis or traumatic brain injury in critically ill children.
    Briassoulis G; Mavrikiou M; Margeli A; Lazaropoulou C; Natsi L; Papassotiriou I; Hatzis T
    Pediatr Pulmonol; 2006 Aug; 41(8):790-5. PubMed ID: 16779848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.
    Arai S; Kurasawa K; Maezawa R; Owada T; Okada H; Fukuda T
    Mod Rheumatol; 2013 Sep; 23(5):872-83. PubMed ID: 22983659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters.
    Sakamoto K; Taniguchi H; Kondoh Y; Johkoh T; Sumikawa H; Kimura T; Nishiyama O; Kato K; Kataoka K; Ono K; Kitaichi M; Hasegawa Y
    Respir Med; 2010 Jan; 104(1):127-33. PubMed ID: 19811899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum KL-6 level and the development of bronchiolitis obliterans syndrome in lung transplant recipients.
    Haberman B; Doan ML; Smith EO; Schecter MG; Mallory GB; Elidemir O
    Pediatr Transplant; 2010 Nov; 14(7):903-8. PubMed ID: 20667031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.